Pioneering Change in Radiotherapy With Biological Adaptive Radiotherapy for Lung Volumetric Modulated Radiotherapy (VMAT) Patients.
[AIMS] To introduce a Biological Adaptive Radiotherapy (BART) framework that incorporates biological effects into adaptive planning, quantify the impact of a short intrafraction interruption on biolog
APA
Kawahara D, Koganezawa AS, et al. (2025). Pioneering Change in Radiotherapy With Biological Adaptive Radiotherapy for Lung Volumetric Modulated Radiotherapy (VMAT) Patients.. Clinical oncology (Royal College of Radiologists (Great Britain)), 48, 103957. https://doi.org/10.1016/j.clon.2025.103957
MLA
Kawahara D, et al.. "Pioneering Change in Radiotherapy With Biological Adaptive Radiotherapy for Lung Volumetric Modulated Radiotherapy (VMAT) Patients.." Clinical oncology (Royal College of Radiologists (Great Britain)), vol. 48, 2025, pp. 103957.
PMID
41160927
Abstract
[AIMS] To introduce a Biological Adaptive Radiotherapy (BART) framework that incorporates biological effects into adaptive planning, quantify the impact of a short intrafraction interruption on biologically effective dose (BED) in stage III non-small cell lung cancer treated with volumetric modulated arc therapy (VMAT), and evaluate a compensation strategy designed to restore target BED while respecting organs-at-risk (OAR) constraints.
[METHODS] We analysed lung non-small cell cancer patients with stage III treated using VMAT with two full arcs. A microdosimetric kinetic model (MKM) was used to calculate BED reductions caused by a 120-minute interruption after the first arc. Compensation plans were generated by converting deviations in biological dose into physical dose adjustments, which were optimised using a treatment planning system (TPS). Dose-volume histograms (DVHs) and other metrics were compared for plans with and without interruptions and after BART compensation.
[RESULTS] Interruption An interruption caused BED reductions in planning target volume, with the dose difference of the D and D differences of 15.7%-16.5% and 5.2%-14.5%, respectively. For a normal lung, volume differences at 5 Gy (V) and 20 Gy (V) ranged from 0.7% to 2.2% and 0.3% to 4.7%, respectively. With dose compensation, the dose differences reduced to 0.8%-1.4% for the D and 1.4%-8.3% for the D. The difference of the V and V also decreased to 1.0%-4.1% and 0.4%-2.6%, respectively. Spinal cord dose constraints were met across all plans.
[CONCLUSION] The BART framework effectively compensates for BED reductions due to short-term treatment interruptions, preserving therapeutic efficacy and adhering to organ at risk (OAR) constraints. This innovative approach represents a transformative advancement in adaptive radiation therapy by integrating biological considerations, enhancing treatment precision and personalisation.
[METHODS] We analysed lung non-small cell cancer patients with stage III treated using VMAT with two full arcs. A microdosimetric kinetic model (MKM) was used to calculate BED reductions caused by a 120-minute interruption after the first arc. Compensation plans were generated by converting deviations in biological dose into physical dose adjustments, which were optimised using a treatment planning system (TPS). Dose-volume histograms (DVHs) and other metrics were compared for plans with and without interruptions and after BART compensation.
[RESULTS] Interruption An interruption caused BED reductions in planning target volume, with the dose difference of the D and D differences of 15.7%-16.5% and 5.2%-14.5%, respectively. For a normal lung, volume differences at 5 Gy (V) and 20 Gy (V) ranged from 0.7% to 2.2% and 0.3% to 4.7%, respectively. With dose compensation, the dose differences reduced to 0.8%-1.4% for the D and 1.4%-8.3% for the D. The difference of the V and V also decreased to 1.0%-4.1% and 0.4%-2.6%, respectively. Spinal cord dose constraints were met across all plans.
[CONCLUSION] The BART framework effectively compensates for BED reductions due to short-term treatment interruptions, preserving therapeutic efficacy and adhering to organ at risk (OAR) constraints. This innovative approach represents a transformative advancement in adaptive radiation therapy by integrating biological considerations, enhancing treatment precision and personalisation.
MeSH Terms
Humans; Radiotherapy, Intensity-Modulated; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Radiotherapy Planning, Computer-Assisted; Organs at Risk; Radiotherapy Dosage